Skip to main content

High-flow nasal cannula may be no safer than non-invasive positive pressure ventilation for COVID-19 patients

To the Editor:

We have read with great interest the Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19) [1]. We are very concerned on the recommendation to use high-flow nasal cannula (HFNC) over non-invasive positive pressure ventilation (NIPPV).

We agree that HFNC has previously demonstrated reduced 90-day mortality compared to NIPPV in patients with acute hypoxemic respiratory failure [2] and that NIPPV has been demonstrated to have increased risk of aerosolized transmission to health care workers [3]. However, the differences in this risk with NIPPV compared to HFNC are largely unknown. Presently, it is known that COVID-19 (SARS-CoV-2) compared to SARS-CoV-1 remains viable in aerosols for at least 3 h with a marginal reduction in infectious titer from 103.5 to 102.7 TCID50 per liter of air [4]. Likewise, it showed a higher stability on plastic and stainless steel than on copper and cardboard, with virus viability seen up to 72 h on these surfaces [4]. This provides a concerning phenomenon for both HFNC and NIPPV as both interfaces are plastic with potential for aerosolization. An important difference is that the NIPPV interface provides a potential closed system (which may be advantageous) whereas HFNC allows patients to frequently touch their faces with continuous exposure to droplets, potentially increasing transmission to inanimate surfaces and hospital workers.

In 2019, Leung and colleagues found that HFNC use was not associated with increased air or contact surface bacterial contamination compared to simple oxygen mask in critically ill patients [5]. Unfortunately, viruses were not included in this study. Likewise, the term “aerosol” is a misnomer as it is well described that larger particle droplets can remain longer in circulation if ambient airflows (as in HFNC) sustain the infectious suspension for a longer duration. This, coupled with data from influenza infections showing aerosolized viruses are infectious at a lower dose than by nasal instillation, makes use of HFNC potentially worrisome [6]. The only known study evaluating SARS development in hospital workers was a retrospective study conducted prior to the widespread use of HFNC showing that development of SARS occurred in tracheal intubation (35%), HFNC 8%, and 38% (NIPPV) [3]; this suggests that both non-invasive (including HFNC) and invasive ventilation approaches carry significant risk.

Undeniably, HFNC provides more comfort to patients and likely improved compliance. However, since the data regarding transmission are unclear, we suggest, in addition to a negative pressure room, reverse isolation protection efforts with patients on HFNC wearing a mask over the nasal interface or a contained respiratory hood.

Availability of data and materials

Not applicable.

References

  1. 1.

    Alhazzani W, Moller MH, Arabi YM, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Crit Care Med Released on March 20. PMID: 32224769. https://doi.org/10.1097/CCM.0000000000004363.

  2. 2.

    Frat JP, Thille AW, Mercat A, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. New Engl J Med. 2015;372(23):2185–96.

    CAS  Article  Google Scholar 

  3. 3.

    Raboud J, Shigayeva A, McGeer A, et al. Risk factors for SARS transmission from patients requiring intubation: a multicentre investigation in Toronto, Canada. PLoS One. 2010;5(5):e10717.

    Article  Google Scholar 

  4. 4.

    van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020;382(16):1564–7. https://doi.org/10.1056/NEJMc2004973.

  5. 5.

    Leung CCH, Joynt GM, Gomersall CD, et al. Comparison of high-flow nasal cannula versus oxygen face mask for environmental bacterial contamination in critically ill pneumonia patients: a randomized controlled crossover trial. J Hosp Infect. 2019;101(1):84–7.

    CAS  Article  Google Scholar 

  6. 6.

    Alford RH, Kasel JA, Gerone PJ, et al. Human influenza resulting from aerosol inhalation. Proc Soc Exp Biol Med. 1966;122(3):800–4.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

Not applicable

Funding

Not applicable.

Author information

Affiliations

Authors

Contributions

KR, PV, and JL all contributed equally to the conception and drafting of this manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Philip A. Verhoef.

Ethics declarations

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Remy, K.E., Lin, J.C. & Verhoef, P.A. High-flow nasal cannula may be no safer than non-invasive positive pressure ventilation for COVID-19 patients. Crit Care 24, 169 (2020). https://doi.org/10.1186/s13054-020-02892-9

Download citation